Oncolytics Biotech Stock Performance
| ONC Stock | CAD 1.45 0.08 5.23% |
Oncolytics Biotech holds a performance score of 12 on a scale of zero to a hundred. The company holds a Beta of -1.44, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncolytics Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncolytics Biotech is expected to outperform it. Use Oncolytics Biotech maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to analyze future returns on Oncolytics Biotech.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Oncolytics Biotech displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 105:1000 | Dividend Date 2018-05-25 | Last Split Date 2018-05-25 |
1 | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Yahoo Finance | 05/06/2025 |
2 | Oncolytics Biotech Downgraded by Jones Trading ONCY Sto - GuruFocus | 05/16/2025 |
3 | Proactive Strategies - news.stocktradersdaily.com | 05/27/2025 |
4 | After Major Oncology Conference, All Eyes Turn to Industry Innovation - Morningstar | 06/12/2025 |
5 | Top Steel Picks for the Coming Infrastructure Boom - The Globe and Mail | 06/25/2025 |
6 | Pelareorep A Breakthrough in Oncolytics Biotechs Fight Against Pancreatic and Breast Cancers A High-Conviction Buy at Current Levels - AInvest | 07/09/2025 |
7 | Cancer Treatment Breakthrough How This Drug Transforms Cold Tumors into Hot, Fighting Multiple Cancer Types - Stock Titan | 07/16/2025 |
8 | What drives Oncolytics Biotech Inc. stock price - Superior trading gains - PrintWeekIndia | 07/24/2025 |
| Begin Period Cash Flow | 34.9 M | |
| Total Cashflows From Investing Activities | -239 K |
Oncolytics |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 77.00 in Oncolytics Biotech on April 27, 2025 and sell it today you would earn a total of 68.00 from holding Oncolytics Biotech or generate 88.31% return on investment over 90 days. Oncolytics Biotech is generating 1.2941% of daily returns assuming 8.1741% volatility of returns over the 90 days investment horizon. Simply put, 73% of all stocks have less volatile historical return distribution than Oncolytics Biotech, and 74% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oncolytics Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1583
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ONC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.17 actual daily | 73 73% of assets are less volatile |
Expected Return
| 1.29 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Oncolytics Biotech is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding it to a well-diversified portfolio.
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -2.14 | ||||
| Return On Asset | -0.76 | ||||
| Current Valuation | 133.5 M | ||||
| Shares Outstanding | 96.6 M | ||||
| Price To Earning | (4.18) X | ||||
| Price To Book | 22.76 X | ||||
| EBITDA | (33.16 M) | ||||
| Net Income | (31.71 M) | ||||
| Cash And Equivalents | 3.63 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 14.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.81 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Earnings Per Share | (0.40) X | ||||
| Market Capitalization | 140.07 M | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Working Capital | 12.19 M | ||||
| Current Asset | 26.92 M | ||||
| Current Liabilities | 2.71 M | ||||
About Oncolytics Biotech Performance
By examining Oncolytics Biotech's fundamental ratios, stakeholders can obtain critical insights into Oncolytics Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Oncolytics Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.57) | (1.65) | |
| Return On Capital Employed | (2.59) | (2.46) | |
| Return On Assets | (1.57) | (1.65) | |
| Return On Equity | (5.30) | (5.04) |
Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech is way too risky over 90 days horizon | |
| Oncolytics Biotech may become a speculative penny stock | |
| Oncolytics Biotech appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech has accumulated about 3.63 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72. | |
| Latest headline from news.google.com: What drives Oncolytics Biotech Inc. stock price - Superior trading gains - PrintWeekIndia |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.